Evidence map›Paper›PMID 40076329›Full record

ArticleMolecules (Basel, Switzerland)2025

Design, Synthesis, and Cytotoxicity Evaluation of Novel Indolin-2-One Based Molecules on Hepatocellular Carcinoma HepG2 Cells as Protein Kinase Inhibitors.

Manal M Kandeel, Mohamed Kamal AbdElhameid, Mohamed Adel, Muhammad Y Al-Shorbagy, Ahmed T Negmeldin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Manal M KandeelDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Mohamed Kamal AbdElhameidDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.ORCID 0000-0001-9898-8093
Mohamed AdelDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Egyptian Russian University, Cairo 11829, Egypt.ORCID 0000-0002-7937-0084
Muhammad Y Al-ShorbagyDepartment of Pharmaceutical Sciences, College of Pharmacy, Gulf Medical University, Ajman 4184, United Arab Emirates.ORCID 0000-0002-5104-6821
Ahmed T NegmeldinDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.ORCID 0000-0003-3399-3435

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of indolinone-based derivatives were designed and synthesized using the hybrid pharmacophoric design approach as cytotoxic kinase inhibitors. The cytotoxic effects of the designed molecules were tested against MCF-7 and HepG-2 cell lines. Compounds

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularDrug DesignIndolesLiver NeoplasmsProtein Kinase InhibitorsApoptosisCell ProliferationCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4ErbB ReceptorsHep G2 CellsHumansMCF-7 CellsMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsCDK2 protein, humanCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4ErbB ReceptorsIndolesindolin-2-oneProtein Kinase InhibitorsVascular Endothelial Growth Factor Receptor-2CDKHepG-2 cellsisatinMCF-7protein kinasesquinazolinestyrosine kinase

Identifiers

PMID40076329
PMCPMC11901902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.